TREATMENT DURATION AND CLINICAL OUTCOMES WITH TUMOR TREATING FIELDS IN SWISS PATIENTS WITH GLIOBLASTOMA: A REAL-WORLD ANALYSIS
Author(s)
Gordon V. Chavez, BA1, Jorge Fernando Nino de Rivera Guzman, MSc2, Bruce Wang, PhD3.
1Senior Manager, HEOR, Novocure, Brooklyn, NY, USA, 2Novocure, Glendale, CO, USA, 3Novocure, New York, NY, USA.
1Senior Manager, HEOR, Novocure, Brooklyn, NY, USA, 2Novocure, Glendale, CO, USA, 3Novocure, New York, NY, USA.
OBJECTIVES: Tumor Treating Fields (TTFields) therapy improved progression-free survival (PFS) in patients with newly diagnosed glioblastoma (GBM) in the EF-14 trial. This study evaluated whether outcomes observed in Swiss clinical practice are consistent with EF-14 findings.
METHODS: This retrospective real-world study included Swiss patients initiating TTFields therapy between 2013 and 2026 using device data and medical records. Patients with a documented treatment start date were included. Time on treatment was measured from TTFields initiation to discontinuation. PFS was measured from treatment initiation to documented progression. Progression events were identified using clinical status indicators, including disease progression, re-radiation, and recurrence-related surgery. Kaplan-Meier analyses were used to estimate treatment duration and PFS. Outcomes were compared descriptively with published EF-14 results.
RESULTS: A total of 520 patients initiated TTFields therapy during the study period. Among patients who discontinued therapy (n=467), mean treatment duration was 9.0 months (SD: 10.3). The 25th, 50th (median), and 75th percentiles for treatment duration were 3.3, 6.2, and 12.0 months, respectively. Progression data were available for 112 patients. Mean PFS was 10.5 months (SD: 10.7). The 25th, 50th (median), and 75th percentiles for PFS were 4.3, 7.1, and 10.9 months, respectively. Median PFS exceeded that reported in EF-14 ([7.1] vs. [6.7] months).
CONCLUSIONS: Outcomes among Swiss patients receiving TTFields therapy in routine practice compared favorably with those observed in EF-14. These findings support the effectiveness of TTFields therapy outside the clinical trial setting and demonstrate the reproducibility of pivotal trial results in real-world care.
METHODS: This retrospective real-world study included Swiss patients initiating TTFields therapy between 2013 and 2026 using device data and medical records. Patients with a documented treatment start date were included. Time on treatment was measured from TTFields initiation to discontinuation. PFS was measured from treatment initiation to documented progression. Progression events were identified using clinical status indicators, including disease progression, re-radiation, and recurrence-related surgery. Kaplan-Meier analyses were used to estimate treatment duration and PFS. Outcomes were compared descriptively with published EF-14 results.
RESULTS: A total of 520 patients initiated TTFields therapy during the study period. Among patients who discontinued therapy (n=467), mean treatment duration was 9.0 months (SD: 10.3). The 25th, 50th (median), and 75th percentiles for treatment duration were 3.3, 6.2, and 12.0 months, respectively. Progression data were available for 112 patients. Mean PFS was 10.5 months (SD: 10.7). The 25th, 50th (median), and 75th percentiles for PFS were 4.3, 7.1, and 10.9 months, respectively. Median PFS exceeded that reported in EF-14 ([7.1] vs. [6.7] months).
CONCLUSIONS: Outcomes among Swiss patients receiving TTFields therapy in routine practice compared favorably with those observed in EF-14. These findings support the effectiveness of TTFields therapy outside the clinical trial setting and demonstrate the reproducibility of pivotal trial results in real-world care.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO66
Topic
Clinical Outcomes, Medical Technologies, Real World Data & Information Systems
Topic Subcategory
Clinical Outcomes Assessment
Disease
Neurological Disorders, Oncology